Fig 2: CCDC106 increased Cyclin A2 and Cyclin B1 expression via AKT activationPhosphorylated AKT (Ser473) was increased by CCDC106 overexpression in A549 cells, and decreased by CCDC106 knockdown in H1299 cells (A) LY294002 treatment rescued CCDC106-induced Cyclin A2 and Cyclin B1 upregulation (B) and NSCLC cell colony formation (C) **P < 0.01.

Fig 3: CCDC106 enhanced NSCLC cell proliferation in vitro and in vivoTransfection efficiency after overexpressing CCDC106 in A549 cells and silencing CCDC106 in H1299 cells, as tested by WB (A) CCDC106 overexpression enhanced A549 cell growth (B) and colony formation (C) while knockdown reduced H1299 cell growth (B) and colony formation C. Average tumor volumes and weights were higher in mice subcutaneously injected with A549-CCDC106 (+) cells compared to controls (D). *P < 0.05, **P < 0.001.

Fig 4: CCDC106 expression in NSCLC specimens and cell linesNegative or weak CCDC106 expression in normal bronchial (A) and alveolar epithelial cells (B) Positive CCDC106 expression in the cytoplasm of lung squamous cell carcinoma (C) and adenocarcinoma cells (D) Kaplan–Meier survival analysis revealed that CCDC106-positive patient overall survival was reduced compared to those without CCDC106 expression (E) CCDC106 expression in HBE cells was lower than in most NSCLC cell lines (except H292) (F) and was localized to the cytoplasm in A549, H1299 and LK2 cells (G).